**CURRICULUM VITAE (truncated at 2000)**

**Name:** **Steven (Steev) Sutton**
Professor of Pharmaceutics & Pharmacokinetics
Department of Pharmaceutical Sciences & Administration
School of Pharmacy
Westbrook College of Health Professions
University of New England
716 Stevens Avenue
Portland, ME 04103-2670
Phone: (207) 221-4173
ssutton1@une.edu

**Education:**

- IDND 30501 (Online): Seminar in College Teaching, Clark University
- Ph.D., Pharmaceutics, State University of New York, School of Pharmacy, Department of Pharmaceutical Sciences
- B.S. in Pharmacy, Cum Laude, Massachusetts College of Pharmacy, College of Pharmacy

**Employment History:**

- 2025-present, Professor, Department of Pharmaceutical Sciences, School of Pharmacy, Westbrook College of Health Professions, University of New England, Portland, Maine
- 2020 – 2025, Associate Professor, Department of Pharmaceutical Sciences, School of Pharmacy, Westbrook College of Health Professions, University of New England, Portland, Maine
- 2016 - 2020, Associate Professor, Department of Pharmaceutical Sciences, College of Pharmacy, University of New England, Portland, Maine
- 2012 – 2016, Chair and Associate Professor, Department of Pharmaceutical Sciences, College of Pharmacy, University of New England, Portland Maine
- 2013 – Awarded tenure as Associate Professor, Department of Pharmaceutical Sciences, College of Pharmacy, University of New England, Portland Maine
- 2011 - 2012, Interim Chair and Associate Professor, Department of Pharmaceutical Sciences, College of Pharmacy, University of New England, Portland Maine
- 2009 - 2011, Associate Professor, Department of Pharmaceutical Sciences, College of Pharmacy, University of New England, Portland, Maine

- 2004 - 2011, Adjunct Appointment, Visiting Scientist/Lecturer, Team Taught Advanced Biopharmaceutics, Department of Pharmaceutics, School of Pharmacy, University of Connecticut
- 2000 - 2009, Head of BioPharmaceutics Group, Pharmaceutical Research and Development, PGRD, Groton, CT

**Academic and Professional Awards:**

- 2012, American Academy of Veterinary Pharmacology & Therapeutics (AAVPT) Fellow; a distinguished research designation attributed to members who have made significant contributions to the profession.
- 2003, American Association of Pharmaceutical Sciences (AAPS) Fellow; a distinguished research designation attributed to <5% of all AAPS members.

**Research Mentoring (Academic)**

*University of New England*

2012 - 2013: Sanh Duong (recipient of a UNE College of Pharmacy Emily Jane Etherton Charitable Lead Trust Student Research Fellowship).
2014 - 2015: Meghan Danley (Marine Sciences, Biology, CAS)
2015: Laura Hitchcock (employee)
2015 – 2016: Amelia Farnham (Independent Study, employee)
2018: Riana Lincoln (Dean's Summer Student Fellowship)
2019: Hershil Kachrani (Dean's Summer Student Fellowship)
2021: Spencer Canham (Dean's Summer Student Fellowship)
2022: Zainab Jabor (Dean's Summer Student Fellowship)
2023: Carmella St. Pierre (Dean's Summer Student Fellowship)
2024: Megan Steele (Dean's Summer Student Fellowship), Robert Patnaude

**Publications – Peer Reviewed Journals (endnotes describe roles):**
**ORCID: 0000-0002-6349-0356**

1. **Sutton, S.C.** and R.D. Hills, Jr. (2025) Role of Nanoplastic in Decreasing the Intestinal Microbiome Ratio: A review of the scope of polystyrene. Toxics, 13 https://www.ncbi.nlm.nih.gov/pubmed/41441257
2. St. Pierre, C., P. Caradonna, M. Steele, **S. C. Sutton** (2025) Plastic nanoparticle toxicity is accentuated in the inflamed intestinal cell model. Nanotoxicology **19** (1): 69-83. https://doi.org/10.1080/17435390.2025.2452851.

3. Jabor, Z. and **S. C. Sutton** (2023). "Effects of Digestion, Cell Culture Media, and Mucous on the Physical Properties, Cellular Effects, and Translocation of Polystyrene and Polymethacrylate Nanoparticles." Toxics **11**(8): 708-720.
4. Hills, R. D., B. A. Pontefract, H. R. Mishcon, C. A. Black, **S. C. Sutton** and C. R. Theberge (2019). "Gut Microbiome: Profound Implications for Diet and Disease." Nutrients **11**(7): 1613. Awarded Best Paper by Journal in 2021.
5. **Sutton, S. C.,** R. Nause and K. Gandelman (2017). "The impact of gastric pH, volume, and emptying on the food effect of ziprasidone oral absorption." The AAPS Journal 19(7): 1084-1090.
6. Thombre, A.G., W.B. Caldwell, D.T. Friesen, S.B. McCray, and **S.C. Sutton**[2], Solid Nanocrystalline Dispersions of Ziprasidone with Enhanced Bioavailability in the Fasted State. Molecular Pharmaceutics, 2012, 9:3526-3534.
7. Claxton, R., Endrenyi, L., Lucas, A., Martinez, M. & **Sutton, S.C.**[1,2]. Estimating product bioequivalence for highly variable veterinary drugs. J Vet Pharmacol Therap, 2012, 35:11-16.
8. **Steven C. Sutton**, The Use of Gastrointestinal Intubation Studies for Controlled Release Development. British Journal of Clinical Pharmacology, 2009. 68(3): p. 342-354.
9. **Sutton, S.C**., Role of Physiological Intestinal Water in Oral Absorption. The AAPS Journal, 2009. 11(2): p. 277-285
10. Sagawa, K., F. Li, R. Liese, and **S. C. Sutton**[5], Fed and fasted gastric pH and gastric residence time in conscious beagle dogs. Journal of Pharmaceutical Sciences, 2009. 98(7): p. 2494-2500.
11. **Sutton, S. C**[2]., L. A. F. Evans, J. H. Fortner, J. M. McCarthy and K. A. Norton, Dog Colonoscopy Model For Predicting Human Colon Absorption. Pharmaceutical Research, 23: 1554-1563, 2006.
12. **Sutton SC**, Hu MS. An Automated Process for Building Reliable Optimal IVIVC Models Based on Monte Carlo Simulations. The AAPS Journal 2006; 8:1-13.
13. **Sutton, S.C**. Companion animal physiology and dosage form performance Advance Drug Delivery Reviews 56: 1383-1398, 2004.
14. Thombre, A., L.E. Appel, P.D. Chidlaw, P.D. Daugherity, F. Dumont, L.A.F. Evans, and **S.C. Sutton**, Osmotic Drug Delivery Using Swellable-Core Technology. Journal Controlled Release, 94: 75-89, 2004.
15. Waterman, K.C. and **S.C. Sutton**, A computational model for particle size influence on drug absorption during controlled-release colonic delivery. Journal of Controlled Release, 2003. 86(2-3): p. 293-304.

16. **Sutton, SC**, MTS Rinaldi JM McCarthy and KE Vukovinsky: A Statistical Method for the Determination of Absorption Rate Constant Estimated Using the Rat Single Pass Intestinal Perfusion Model and Multiple Linear Regression. Journal of Pharmaceutical Sciences 91:1046-1053, 2002.
17. **Sutton, SC**, MTS Rinaldi and K Vukovinsky: Comparison of the Gravimetric, Phenol Red and $^{14}$C-PEG-3350 Methods to Determine Water Absorption in the Rat Single Pass Intestinal Perfusion Model. AAPS Pharm Sci, 3 (3) article 25, 2001, pp1-7. (http://www.pharmsci.org/scientificjournals/pharmsci/journal/01_25.html)

**Chapters and Books (endnotes describe roles):**

1. **Sutton, S. C**. (2017). Chapter 3. Drug Administration and Drug Absorption. Basic Pharmacokinetics and Pharmacodynamics. S. Rosenbaum. Hoboken, NJ, Wiley: 35-70.
2. **Sutton, S. C**. (2017). Chapter 9. Pharmacokinetics of Extravascular Drug Administration. Basic Pharmacokinetics and Pharmacodynamics. S. Rosenbaum. Hoboken, NJ, Wiley: 201-224.
3. **Sutton, S.C**: Chapter 6: "Biopharmaceutics and veterinary drug delivery", In: Animal Health Drug Delivery, Michael Rathbone (Ed), Controlled Release Society, The Springer Publishing Company, New York 2013.
4. **Sutton, S.C**: Chapter 4: "Anatomy and physiology of the companion animal", In: Animal Health Drug Delivery, Michael Rathbone (Ed), Controlled Release Society, The Springer Publishing Company, New York 2013.
5. Jaymin Shah, **Steve Sutton**[5], Susan Way, Gayle Brazeau: "Parenteral Formulations: Local Injection Site Reaction and Muscle Tolerance", In: Encyclopedia of Pharmaceutical Technology Third Edition, James Swarbrick (ed) Informa Healthcare USA, Inc., New York 2013.
6. **Sutton, S.C**.[1], P. Smith: Chapter 3. Animals Suitable for Modeling Controlled Release, In: "Oral Controlled Release", Clive Wilson, Brigitte Skalsky & Patrick Crowley (eds), Controlled Release Society, The Springer Publishing Company, New York, 2011.
7. **Sutton**, S.C.: Chapter 5. Methods to Assess Pain, Irritation, and Muscle Damage Following Injection, In: Injectable Drug Development: Techniques to Reduce Pain and Irritation, PK Gupta and GA Brazeau (eds), Interpharm Press, Englewood, CA, 2004, pp 91-118

**Book Reviews**

Sutton, S.C., Biopharmaceutics Modeling and Simulations: Theory, Practice, Methods, and Applications By Kiyohiko Sugano. ChemMedChem, 2013.

**Invited Presentations (not "Posters"; posters are listed under "Abstracts":**

1. T. Heimbach, S. **Sutton**, "Regulatory Examples and History of PBPK and ACAT Models", GastroPlus Webinar June 20th, 2020.
2. **Sutton**, SC. Challenges When Working with Different Animal Species. USP Workshop on In vitro Testing for Meeting Future Challenges for Veterinary Dosage Forms, March 14–15, 2016 USP Meetings Center, Rockville, Maryland.
3. **Sutton**, SC. Interspecies intestinal differences and impact on oral dosage forms for animal health" to be presented at the joint CRS/AAPS workshop "Animal Health Drug R&D: Formulation, Delivery and Development to Market", November 1-2, 2014, in San Diego.
4. **Sutton**, SC. The anatomy & physiology of interspecies' biopharmaceutics, presented at the "Interspecies clinical pharmacology dosing concepts" mini-symposia, at the 2014 Annual Meeting of the Controlled Release Society, July 13-16, 2014, in Chicago.
5. **Sutton**, SC. Predictive Animal Models for Assessing Long-Acting Formulations for Human and Animal Health, presented at the Inaugural Controlled and Modified Drug Release Conference in Philadelphia, PA on May 7-8, 2014.
6. **Sutton**, SC. Critical Features of Solubility and Permeability that can Limit the Food Effect, presented at the 2nd annual Drug Formulation & Bioavailability – West Coast, in San Diego, CA, on June 2-3, 2014.
7. **Sutton**, S. C.: Biopharmaceutics and Pharmacokinetics of the Food Effect, presented at the Roundtable: *When Food Impacts Oral Drug Exposure: The Nature and Study of the Food Effect*. AAPS National Meeting, San Antonio, Nov., 2013.
8. **Sutton** SC. Utilizing in silico, in vitro and preclinical methods to optimize your clinical prediction from biopharmaceutic modeling. ExlPharma's 2nd Enhancing Drug Bioavailability and Solubility Conference, Boston, MA January, 2013.
9. Caldwell, W.B., S.B. McCray, D.T. Friesen, C. Craig, S. Konagurthu, A.G. Thombre, S. Shamblin, M. Roy, K. Sagawa, and S.C. **Sutton**. Modulation of Dissolution Rate and Pharmacokinetics for a High-Energy Nanocrystalline Form of Ziprasidone. in AAPS National Meeting. 2012. Chicago: AAPS.
10. **Sutton**, S.C. and R. Nause: Explaining the Positive Food Effect for Ziprasidone HCl Observed in the Clinic. in AAPS National Meeting. 2012. Chicago: AAPS.

**11.** S.C. **Sutton**: *Preclinical Models and Simulation Tools: Successful Integration and Optimized Clinical Outcome* joint Roundtable by the Biopharmaceutics & Physical Pharmacy and the Drug Metabolism & Pharmacokinetics Sections of the AAPS, Sunrise Session, AAPS National Meeting, Chicago, October, 2012.

**12.** S.C. **Sutton**: Counterfeit Pharmaceuticals: A Global Problem Come Home, presented as the Keynote Speaker at the 125th Anniversary Celebration of the University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Sept., 2011.

**13.** S.C. **Sutton**, JL Morton: "A Collaborative Partnership Poised to Influence Counterfeit Detection", Counterfeits, 6th Global Forum on Pharmaceutical Anti-Counterfeiting, London, May 12, 2011.

**14.** S. C. **Sutton**: Use of GastroPlus™ models in veterinary research and development, Presented at the Controlled Release Society National Meeting in Portland, OR, July 12, 2010.

**15.** S. C. **Sutton**: The Use of Gastrointestinal Intubation Studies For Controlled Release Development, presented at the Drug Metabolism Discussion Group (a Simcyp Company Consortium), in Sheffield, UK, February, 2010.

**16.** S. C. **Sutton**: Minimizing the Guesswork of Early Human Dose Predictions: Application of PK prediction methodologies including PBPK, presented at the AAPS Sunrise Session at the National AAPS Meeting in Los Angeles, November, 2009.

**17.** S. C. **Sutton**: State of the Art Review: Predicting Food Effects, presented at the AAPS Workshop on Evolving Science and Technology in Physical Pharmacy and Biopharmaceutics in Baltimore, Maryland, May, 2009.

**18.** S. C. **Sutton**: Role of Physiological Intestinal Water in Oral Absorption, presented at the AAPS workshop Application of Biopharmaceutics in Modeling & Simulations at the National AAPS Meeting in George, Atlanta, November, 2008.

**19.** Sheri L. Shamblin and S C. **Sutton**. Choosing the Appropriate Drug Form for Controlled Release using Computational Methods to Model In Vivo Performance. Fine Particle Society National Meeting, San Diego, CA, Dec 18-21, 2006.

**20.** S. C. **Sutton**. The Use Of Computer Simulation Software To Predict The In Vivo Performance Of IR & CR Formulations In Humans. Invited Pharmaceutics Seminar Speaker at: Massachusetts College of Pharmacy and Health Sciences, Boston, MA, December 16, 2006.

**21.** S. C. **Sutton**. GI Transit Times in Animals. 2nd Joint AAPS/AAVPT/CRS workshop 2006 "The Challenges of Delivering Drugs to Animals", San Antonio, TX, October 27-29, 2006.

22. Sagawa, K. & **Sutton**, S. C, (2006). Gastrointestinal physiology: species differences. 2nd Joint AAPS/AAVPT/CRS workshop 2006 "The Challenges of Delivering Drugs to Animals", San Antonio, TX, October 27-29, 2006.
23. S. C. **Sutton**. Physiologic Factors Related to Drug Absorption, presented as lectures at: University of Connecticut School of Pharmacy graduate level course PH 334 “Advanced Biopharmaceutics”, Storrs, CT October, 2006.
24. S. C. **Sutton**. Companion animal physiology and dosage form performance. CRS 2006 Annual Meeting & Exposition, in Vienna, Austria on July 26, 2006.
25. S. C. **Sutton**. Biopharmaceutical Properties that Impact the Successful Prediction of In Vivo Performance of Oral Dosage Forms. AAPS Northeastern Pharmaceutical Discussion Group, Rocky Hill, CT, April 2005.
26. S. C. **Sutton**. Physiologic Factors Related to Drug Absorption, presented as lectures at: University of Connecticut School of Pharmacy graduate level course PH 334 “Advanced Biopharmaceutics”, Storrs, CT October 12,, 2004.
27. S. C. **Sutton**. "Factors influencing oral bioavailability of drug molecules”, to the North-Eastern Regional Meeting of the American Chemical Society, Arqule in Woburn, MA (12 Dec. 2002).
28. S. C. **Sutton**. Optimal/Reliable IVIV Correlation Model, presented to the Dept. Pharmaceutics Graduate Students PHC502, SUNYAB, Oct 1, 2002
29. S. C. **Sutton**. The Use of a Pharmacokinetic Profile to Drive the Formulation Development of Modified Release Dosage Forms, in AAPS Conference on Pharmaceutics and Drug Delivery. AAPS, Arlington, VA (April 24, 2002).
30. S. C. **Sutton**. Using Monte Carlo Simulation to Aid in the Selection of the Optimal IVIV Correlation Model presented at the workshop: In vitro – in vivo correlation symposium 2001: Methods, Applications & Future Directions in Baltimore, MG on September 10-11, 2001.
31. S. C. **Sutton**. Animal physiology, drug disposition and dosage form performance. Presented at the Veterinary Science Section of the 28$^{th}$ International Symposium on Controlled Release of Bioactive Materials, June 23-27, 2001, San Diego, CA.
32. S. C. **Sutton**. Detergents and other barrier breakers Presented at the Barriers to Entry: New Directions in Drug Delivery Systems, Davidson Conference Center, A.E. Mann Institute for Biomedical Engineering, USC School of Pharmacy, Los Angeles, CA on March 31, 2001.

## Patents

1. Dosage Forms of Cholesteryl Ester Transfer Protein Inhibitors and HMG-CoA Reductase Inhibitors", Patent Assignee: Pfizer Prod Inc (Pfizer), Inventor: Curatolo W J; Friesen, D T; **Sutton** S C; US 2005/0038007 A1; Pub Date: Feb., 15, 2005.
2. Imran Ahmed, Leah Appel, Walter Christian Babcock, Dwayne Thomas Friesen, Scott Herbig, David Keith Lyon, Sheri L. Shamblin, Ravi Mysore Shanker, Daniel Tod Smithey, Steven C. **Sutton**, Avinash G. Thombre, Kenneth C. Waterman, Sustained release dosage forms of ziprasidone, in USPTO, I. Pfizer, Editor. filed Sep. 2, 2003. US 2007/0190129.
3. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor. Patent Assignee: Pfizer Prod Inc (Pfizer), Inventors: Curatolo W J; **Sutton** S C; Appel, L A; US 2003/0198674 A1; Pub Date: Oct. 23, 2003.
4. Curatolo, W., J. Nightingale, R. Shanker, and S. **Sutton**, Basic drug compositions with enhanced bioavailability, in USPTO, I. Pfizer, Editor. 2003, Pfizer, NY, NY: International Patent No A61K 4732; A61K 914
5. Drug composition comprises basic drug or drug forming zwitterion admixed with polymer e.g. cellulose acetate trimellitate, Patent Assignee: Pfizer Prod Inc (Pfizer), Inventor: Curatolo W J; Nightingale J A S; Shanker R M; **Sutton** S C; Nightingale J A , 00300587.3-2114, #EP1027885A2, #US6548555B1.

**Abstracts (these are "Posters", not yet published as manuscripts; endnotes describe roles)**

1. **Sutton, S. C**. and R. D. Hills. "Role of nanoplastics in decreasing the intestinal microbiome ratio: A review of the scope of polystyrene." Microplastics and Human Health, Santa Fe, NM, Jan 11-14, 2026.
2. Steele, Megan, P. Caradonna, **S.C. Sutton**. Plastic nanoparticle toxicity is accentuated in the inflamed intestinal cell model. SoT Annual Meeting, Orlando, FL, 20 Mar 2025.
3. Steele, Megan, P. Caradonna, **S.C. Sutton**. Plastic nanoparticle toxicity is accentuated in the inflamed intestinal cell model. BSMSE Annual Meeting, University of Maine, Orono, Maine, 20 Sep 2024.
4. St. Pierre, C., P. Caradonna, **S.C. Sutton**. Modification of an *In Vitro* Intestinal Inflammation Model that Realistically Predicts Cellular Damage from Low Density Nanoplastic. Maine Research Symposium, University of Maine, Orono, Maine, 27 Mar 2024.
5. Jabor, Z., **S. C. Sutton**. Translocation of Polystyrene and Polymethacrylate Nanoparticles Across Caco-2 and HT-29 Cell Monolayer. First Annual Maine Research Symposium on Biomedical Science and Engineering, UNE, Portland, ME, 12 October 2022.

6. Jabor, Z., **S. C. Sutton**. Translocation of Polystyrene and Polymethacrylate Nanoparticles Across Caco-2 and HT-29 Cell Monolayer. Maine Pharmacists Association Fall Convention, Portland, ME, 14 October 2022.
7. Canham, S., **S. C. Sutton**. Effects of in vitro digestion on the impact of plastic nanoparticles in an in vitro intestinal model. SoP Dean's Research Day, UNE, Portland, ME 1 September 2021.
8. Kachrani, H., A. Farnham, D. Brazeau, S. C. **Sutton**. Genetic evidence for the impact of inflammation caused by orally ingested nanoparticles of plastic (likely food contaminants) on an in vitro model of the gut. Maine Pharmacy Association Fall Convention, Portland, ME 14 September 2019.
9. Kachrani, H., A. Farnham, D. Brazeau, S. C. **Sutton**. Genetic evidence for the impact of inflammation caused by orally ingested nanoparticles of plastic (likely food contaminants) on an in vitro model of the gut. CoP Dean's Research Day, UNE, Portland, ME 21 August 2019.
10. Hurley, B., Farnham, A., Brazeau, D., **Sutton**, S.C. Determining Whether Gene Toxicity from Acute Exposure of Plastic Nanoparticles and the Polycyclic Aromatic Hydrocarbon – Benzo[a]pyrene are Additive. UNECOM Research Forum September 2018.
11. Lincoln, R., S. C. **Sutton**. The effects of B[a]P on an in vitro model of the human GI immune system. Maine Pharmacy Association Fall Convention, Portland, ME 22 September 2018.
12. Lincoln, R., S. C. **Sutton**. The effects of B[a]P on an in vitro model of the human GI immune system. CoP Dean's Research Day, UNE, Portland, ME 23 August 2019.
13. Farnham, A., Brazeau, D., **Sutton**, S.C. Impact of polystyrene particles and benzo [a] pyrene (B[a]P) on the genotoxicity of an in vitro intestinal model. CoP Dean's Research Day, UNE, Portland, ME 30 April 2018.
14. Farnham, A., S.C. **Sutton**. Genetic modifications and translocation of polystyrene and Benzo[a]pyrene in a human intestinal 9:1 Caco-2:HT29 MTX cell mono-layer model. ASHP Midyear Mtg, Orlando, Fl, 3-7 Dec 2017.
15. **Sutton, S. C**. Effect of the Method of Taking Notes on Pharmaceutics Students Assessments. AACP National Meeting. Nashville, TN, 17 July 2017.
16. A Farnham, SH Stafford, SC **Sutton**: Impact of Dose on Amount of Polystyrene Nanoparticles Translocated Across Caco-2 Cell Monolayers, AAPS NERDG Annual Meeting, Farmington, CT, April 20, 2017.

17. A Farnham, SH Stafford, SC **Sutton**: Impact of Dose on Amount of Polystyrene Nanoparticles Translocated Across Caco-2 Cell Monolayers, UNE College of Pharmacy Student Research Day, Portland, ME, December 8, 2016.
18. A Farnham, SC **Sutton**: An HT29 Cell Monolayer Model to Investigate the Cumulative Genotoxic Effects of POPs and Nanoparticles, AAPS NERDG Annual Meeting, Farmington, *CT*. April 19, 2016.
19. Duong, S. and S. C. **Sutton**[3]: Predicting the Physiologically Relevant Precipitation Rate of Weakly Basic Drugs Using Potentiometric Titration. AAPS National Meeting, San Antonio, TX, Nov., 2013.
20. B. Caldwell, S. McCray, D. Friesen, C. Craig. S. Konagurthu, A. Thombre, S. Shamblin, M. Roy, K. Sagawa, S. **Sutton**[4]: Modulation of Dissolution Rate and Pharmacokinetics for a High-Energy Nanocrystalline Form of Ziprasidone, presented at presented at AAPS Annual Meeting, Chicago, DC Oct, 2012.
21. **SC Sutton**[1], LA Harding, RA Carrier: Rapid in vitro determination of precipitation rates in biorelevant media, presented at AAPS Annual Meeting, Washington, DC Oct, 2011.
22. J. O'Donnell, K. Brighty, J. Engtrakul, M. Fichtner, T. Gootz, J. Hardink, A. Hazra, L. Lamb, Julian Lo, A. Marfat, A. Marra, D. McLeod, R. Monahan, L. Price, K. Soma, S. **Sutton**[5], and J. Winton: Physiologically-Based Pharmacokinetic Modeling of Sulopenem Prodrugs: Impact of Luminal Stability on Fraction of Dose Absorbed, presented at ICAAC/IDSA 46th Annual Meeting, Washington, DC Oct 25-28, 2008.
23. K. Sagawa, R. Liese, S.C. **Sutton**[2] and D. West Inter- and Intra–Individual Variability of Gastric pH in Dogs, presented at the AAPS National Meeting in San Diego, CA November 11-15, 2007.
24. Shamblin, S. L. and S. C. **Sutton**[3]: Choosing the Appropriate Drug Form for Controlled Release using Computational Methods to Model In Vivo Performance; presented at the Fine particle Society National Meeting in San Diego, CA Dec 18-21, 2006.
25. K. Sagawa, E. Novak, J. Shah, S.C **Sutton**, D. West. Pharmacokinetics of Compound X in Beagle Dogs Following Intramuscular (IM) Administration of Aqueous Nano-Suspension Depot Formulations. AAPS. San Antonio, 2006.
26. E. Novak, A. Berchielli, E. Connolly, K. Sagawa, S.C. **Sutton**, D.A. West. Scintigraphic Evaluation of the In Vivo Performance of Matrix Tablets and the Effect of Tablet Breaking Force in Fed and Fasted Dogs. AAPS. San Antonio, 2006.

**27.** D.A.West, C.A.Ashton*, E.K.Eisenhart, T.Ryan, K.Sagawa, S.C.**Sutton**, A.G.Thombre, T.Tritto. A Potential Use for the Ferret Emesis Model: Testing Clinical Oral Drug Formulations. AALAS National Meeting, Salt Lake City, UT, October 15-19, 2006.

**28.** Cosker TA, Lopez ME, Wang HF, Smith WM, **Sutton** SC, Thombre AG. Colonic Absorption of CP-724,714 in Fasted Beagle Dogs. AAPS. San Antonio, 2006.

**29.** West, D. A., J. H. Fortner, S. C. **Sutton**, K. Sagawa, E. N. Novak, K. L. Rogers, M. L. Volberg, J. Trombley, L. A. F. Evans and J. M. McCarthy (2005). Canine Model for Colonic Drug Absorption. 56th AALAS National Meeting, St. Louis, MO, November 6-10, 2005.

**30.** Cosker TA, Lopez ME, Wang HF, Smith WM, **Sutton** SC, Thombre AG. Colonic Absorption of CP-724,714 in Fasted Beagle Dogs. Controlled Release Society. Miami, FL, 2005.

**31.** Sutton, S. C. (2005). Biopharmaceutical Properties that Impact the Successful Prediction of In Vivo Performance of Oral Dosage Forms. AAPS Annual Meeting and Exposition, Nashville, TN, AAPS.

**32.** Sutton, S.C., M.T. am Ende, L.A. Miller, M. D. Likar, J.A. Alderman, J.M. Scavone: The Development of an IVIVC for a Controlled Release Formulation of the Poorly Water-Soluble Compound Sertraline, Using GastroPlus®: Clinical Results, CRS National Meeting, Glasgow, Scotland, July 19-21, 2003.

**33.** Evans, LAF, **Sutton** SC: Canine Model to Predict Colonic Microflora Degradation and Non-Specific Adsorption of Compounds, NERDG meeting, Rocky Hill, CT, April 28, 2003.

**34.** Sutton, S.C.: Use of the Dog Colon Model and a Physiologic-Pharmacokinetic Computer Model to Simulate Controlled Release Plasma Profiles. in Proceed Int'l Symp Control Rel Bioact Mater. 2000. Paris: The Controlled Release Society, Inc.

**35.** Rahl, P., JM McCarthy and SC **Sutton**: The Precipitation Kinetics of Weak Bases in Gastric to Intestinal Transfer Studies, NERDG Meeting, Rocky Hill, CT, 2000.

---

[1] Group leader, responsible for editing & style, coordinating contributions of coauthors, final say on wording.
[2] Equally contributing coauthor.
[3] Primary author, responsible for drafting, defining study, collecting most of the data, final manuscript.
[4] Designed dog studies, study leader, reviewed/analyzed results, reviewed manuscript.
[5] Designed model, wrote code, provided data, conclusions.